Table 1.
Comparison of antivascular endothelial growth factor agents in the treatment of central retinal vein occlusiona
| Study | Treatment groups | BCVA gain of ≥15 letters | BCVA loss of ≥15 letters | Mean BCVA change (letters) | Mean change in CRT (µm) |
|---|---|---|---|---|---|
| GALILEO 2013 | Aflibercept 2.0 mg (n=106) | 60.2% (62/103) | Not reported | +18.0 | −448.6 |
| Sham (n=71) | 22.1% (15/68) | Not reported | +3.3 | −169.3 | |
| Copernicus 2012 | Aflibercept 2.0 mg (n=114) | 56.1% (64/114) | 1.8% (2/114) | +17.3 | −457.2 |
| Sham (n=74) | 12.3% (9/73) | 27.4% (20/73) | −4.0 | −144.8 | |
| CRUISE 2010 | Ranibizumab 0.3 mg (n=132) | 46.2% (61/132) | 3.8% (5/132) | +12.7 | −433.7 |
| Ranibizumab 0.5 mg (n=130) | 47.7% (62/130) | 1.5% (2/130) | +14.9 | −452.3 | |
| Sham (n=130) | 16.9% (22/130) | 15.4% (20/130) | +0.8 | −167.0 | |
| ROCC 2010 | Ranibizumab 0.5 mg (n=16) | 53.3% (8/15) | 13.3% (2/15) | +12.0 | −304.0 |
| Sham (n=16) | 14.3% (2/14) | 4/14 (28.6%) | −1.0 | −151.0 | |
| Epstein 2012 | Bevacizumab 1.25 mg (n=30) | 60.0% (18/30) | 6.7% (2/30) | +14.1 | −426.0 |
| Sham (n=30) | 20.0% (6/30) | 23.3% (7/30) | −2.0 | −102.0 | |
| Wroblewski 2009 | Pegaptanib sodium 0.3 mg (n=33) | 36.4% (12/33) | 9.1% (3/33) | +7.1 | −243.0 |
| Pegaptanib sodium 1.0 mg (n=33) | 39.4% (13/33) | 6.1% (2/33) | +9.9 | −179.0 | |
| Sham (n=32) | 28.1% (9/32) | 31.2% (10/32) | −3.2 | −148.0 |
aData reported at 6-month follow-up visit for each study. VEGF = Vascular endothelial growth factor, CRVO = Central retinal vein occlusion, BCVA = Best-corrected visual acuity, CRT = Central retinal thickness